{"hands_on_practices": [{"introduction": "The intricate process of pre-mRNA splicing begins with the precise recognition of splice sites by protein factors. This exercise grounds the complex biology of spliceosome assembly in fundamental biophysical principles by modeling the interaction between the U2AF65 protein and its target polypyrimidine tract. By deriving and applying the relationship between the dissociation constant ($K_d$), protein concentration, and binding site occupancy, you will develop a quantitative understanding of how changes in binding affinity, often caused by genetic variants, can directly impact the efficiency of forming the pre-spliceosome A complex [@problem_id:4378116].", "problem": "In the context of spliceosome assembly at the $3'$ splice site of a pre-messenger ribonucleic acid (pre-mRNA), the U2 auxiliary factor, $65$-kilodalton subunit (U2AF2, commonly U2AF65), binds the polypyrimidine tract to enable recruitment of the U2 small nuclear ribonucleoprotein (U2 snRNP), forming the pre-spliceosome A complex. Consider a single binding site model in which U2AF65 ($L$) binds a polypyrimidine site ($S$) to form the complex ($SL$) at thermodynamic equilibrium governed by the law of mass action. The dissociation constant is defined as $K_{d} = \\frac{[S][L]}{[SL]}$, and the site conservation is $[S]_{\\text{tot}} = [S] + [SL]$. Under nuclear conditions where the ligand is in excess relative to sites, assume $[L]$ in the binding equation equals the measured nuclear free concentration.\n\nA clinically observed sequence variant in the polypyrimidine tract increases U2AF65 binding affinity, changing the dissociation constant from $K_{d} = 100$ nM (reference) to $K_{d} = 50$ nM (variant). The nuclear free concentration of U2AF65 is $[L] = 100$ nM in both cases, and all other assembly factors (for example, splicing factor $1$ (SF1), the U2 small nuclear ribonucleoprotein (U2 snRNP), and the U2 auxiliary factor, $35$-kilodalton subunit (U2AF1, commonly U2AF35)) are non-limiting so that the probability (or steady-state rate) of A complex formation is directly proportional to the occupancy of U2AF65 on the polypyrimidine site.\n\nStarting only from the mass action definition of $K_{d}$ and site conservation, derive the expression for the fractional occupancy $\\theta$ as a function of $K_{d}$ and $[L]$, then evaluate $\\theta$ for the variant ($K_{d} = 50$ nM) and for the reference ($K_{d} = 100$ nM) at $[L] = 100$ nM. Using the proportionality assumption described above, compute the fold-change in A complex formation for the variant relative to the reference as the ratio of occupancies. Provide only this fold-change as your final answer, expressed as a single exact number with no units.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the principles of biochemical equilibrium, well-posed with sufficient and consistent information, and objective in its formulation. The problem addresses a standard model of protein-ligand binding as applied to a critical step in pre-mRNA splicing. We may therefore proceed with a formal solution.\n\nThe problem asks for the derivation of the fractional occupancy ($\\theta$) of a binding site and the calculation of the fold-change in this occupancy due to a mutation that alters the binding affinity.\n\nFirst, we derive the expression for fractional occupancy, $\\theta$. The fractional occupancy is defined as the ratio of the concentration of Ligand-bound Sites, $[SL]$, to the total concentration of sites, $[S]_{\\text{tot}}$.\n$$\n\\theta = \\frac{[SL]}{[S]_{\\text{tot}}}\n$$\nThe total concentration of sites is the sum of the free (unbound) sites, $[S]$, and the bound sites, $[SL]$. This is given by the site conservation equation:\n$$\n[S]_{\\text{tot}} = [S] + [SL]\n$$\nSubstituting this into the expression for $\\theta$ yields:\n$$\n\\theta = \\frac{[SL]}{[S] + [SL]}\n$$\nTo express $\\theta$ as a function of the ligand concentration, $[L]$, and the dissociation constant, $K_d$, we use the definition of $K_d$ provided by the law of mass action for the binding equilibrium $S + L \\rightleftharpoons SL$:\n$$\nK_d = \\frac{[S][L]}{[SL]}\n$$\nWe can rearrange this equation to solve for the concentration of free sites, $[S]$:\n$$\n[S] = \\frac{K_d [SL]}{[L]}\n$$\nNow, we substitute this expression for $[S]$ into our equation for $\\theta$:\n$$\n\\theta = \\frac{[SL]}{\\left(\\frac{K_d [SL]}{[L]}\\right) + [SL]}\n$$\nAssuming the binding reaction occurs (i.e., $[SL] \\neq 0$), we can divide the numerator and the denominator by $[SL]$:\n$$\n\\theta = \\frac{1}{\\frac{K_d}{[L]} + 1}\n$$\nTo simplify the form, we can multiply the numerator and denominator by $[L]$:\n$$\n\\theta = \\frac{[L]}{K_d + [L]}\n$$\nThis is the required expression for fractional occupancy as a function of $K_d$ and $[L]$.\n\nNext, we evaluate the fractional occupancy for both the reference and the variant polypyrimidine tracts. The problem states the free nuclear concentration of the U2AF65 ligand is $[L] = 100$ nM.\n\nFor the reference sequence, the dissociation constant is $K_{d, \\text{ref}} = 100$ nM. The fractional occupancy, $\\theta_{\\text{ref}}$, is:\n$$\n\\theta_{\\text{ref}} = \\frac{[L]}{K_{d, \\text{ref}} + [L]} = \\frac{100 \\text{ nM}}{100 \\text{ nM} + 100 \\text{ nM}} = \\frac{100}{200} = \\frac{1}{2}\n$$\n\nFor the variant sequence, the dissociation constant is $K_{d, \\text{var}} = 50$ nM, reflecting a higher binding affinity (lower $K_d$). The fractional occupancy, $\\theta_{\\text{var}}$, is:\n$$\n\\theta_{\\text{var}} = \\frac{[L]}{K_{d, \\text{var}} + [L]} = \\frac{100 \\text{ nM}}{50 \\text{ nM} + 100 \\text{ nM}} = \\frac{100}{150} = \\frac{2}{3}\n$$\n\nFinally, we compute the fold-change in A complex formation for the variant relative to the reference. The problem states that the probability (or steady-state rate) of A complex formation is directly proportional to the U2AF65 occupancy, $\\theta$. Let the rate of A complex formation be $R$. Then $R \\propto \\theta$, which can be written as $R = c \\cdot \\theta$ for some constant of proportionality $c$.\n\nThe fold-change is the ratio of the rate for the variant to the rate for the reference:\n$$\n\\text{Fold-change} = \\frac{R_{\\text{var}}}{R_{\\text{ref}}} = \\frac{c \\cdot \\theta_{\\text{var}}}{c \\cdot \\theta_{\\text{ref}}} = \\frac{\\theta_{\\text{var}}}{\\theta_{\\text{ref}}}\n$$\nSubstituting the calculated occupancy values:\n$$\n\\text{Fold-change} = \\frac{2/3}{1/2} = \\frac{2}{3} \\times \\frac{2}{1} = \\frac{4}{3}\n$$\nThe variant sequence leads to a $4/3$-fold increase in the formation of the pre-spliceosome A complex compared to the reference sequence under these conditions.", "answer": "$$\n\\boxed{\\frac{4}{3}}\n$$", "id": "4378116"}, {"introduction": "Moving from individual molecular interactions to a transcriptome-wide view, this practice focuses on the essential task of quantifying alternative splicing events from RNA sequencing data. You will learn to calculate the \"Percent Spliced-In\" ($\\Psi$), a standard metric in splicing analysis, using junction-spanning read counts from a hypothetical precision oncology panel. This exercise highlights the critical importance of correcting for technical biases such as sequencing depth, effective junction length, and detection efficiency to derive an accurate and biologically meaningful measure of splicing change, $\\Delta\\Psi$ [@problem_id:4378180].", "problem": "In targeted ribonucleic acid (RNA) sequencing for precision oncology panels, cassette exon inclusion events are routinely quantified to evaluate alternative splicing changes linked to disease mechanisms and therapeutic response. Starting from the Central Dogma of molecular biology and the definition of pre-messenger RNA (pre-mRNA) processing, consider that junction-spanning reads mapping uniquely to inclusion-supporting and exclusion-supporting splice junctions sample isoform abundances proportional to their effective detectable lengths and assay efficiencies, scaled by the sequencing depth. Assume the following foundational base:\n- Pre-mRNA splicing partitions transcripts into isoforms that either include or exclude a cassette exon.\n- Under uniform fragmentation and unbiased sampling conditional on assay efficiency, expected junction reads are proportional to the product of isoform abundance, effective detectable junction length, assay efficiency, and library size.\n- Condition-level inclusion fraction is estimated from replicates by pooling corrected counts that remove library size, effective length, and efficiency effects.\n\nA targeted panel measures a single cassette exon event in a tumor-normal pair, each with two biological replicates. For each replicate $j$, denote by $I_{j}$ the deduplicated inclusion junction read count and by $E_{j}$ the deduplicated exclusion junction count. Let $s_{j}$ be the sampleâ€™s library size in millions of mapped reads. Event-specific parameters determined by external controls are the effective detectable junction lengths $L_{I} = 140$ nucleotides and $L_{E} = 160$ nucleotides, and the junction-specific detection efficiencies $\\alpha_{I} = 0.90$ and $\\alpha_{E} = 0.95$.\n\nData:\n- Normal condition:\n  - Replicate $\\mathrm{N}_{1}$: $I_{\\mathrm{N}_{1}} = 480$, $E_{\\mathrm{N}_{1}} = 1520$, $s_{\\mathrm{N}_{1}} = 40$.\n  - Replicate $\\mathrm{N}_{2}$: $I_{\\mathrm{N}_{2}} = 720$, $E_{\\mathrm{N}_{2}} = 2100$, $s_{\\mathrm{N}_{2}} = 60$.\n- Tumor condition:\n  - Replicate $\\mathrm{T}_{1}$: $I_{\\mathrm{T}_{1}} = 2200$, $E_{\\mathrm{T}_{1}} = 800$, $s_{\\mathrm{T}_{1}} = 50$.\n  - Replicate $\\mathrm{T}_{2}$: $I_{\\mathrm{T}_{2}} = 2600$, $E_{\\mathrm{T}_{2}} = 900$, $s_{\\mathrm{T}_{2}} = 55$.\n\nUse the foundational base to derive the inclusion fraction estimator for a condition by pooling bias-corrected, length-normalized counts across replicates. Then compute the tumor-minus-normal change in percent spliced-in, $\\Delta \\Psi$, for this exon event. Express $\\Delta \\Psi$ as a decimal fraction with no units, and round your final answer to four significant figures.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the principles of molecular biology and bioinformatics, specifically RNA sequencing analysis. It is well-posed, providing all necessary data and definitions for a unique solution. The language is objective and the parameters are realistic.\n\nThe core task is to compute the change in the \"percent spliced-in\" ($\\Psi$) of a cassette exon between a tumor and a normal condition. The value of $\\Psi$ represents the proportion of transcripts that include the exon. It is defined as:\n$$\n\\Psi = \\frac{\\theta_I}{\\theta_I + \\theta_E}\n$$\nwhere $\\theta_I$ is the abundance of the inclusion isoform and $\\theta_E$ is the abundance of the exclusion isoform.\n\nThe problem states that the expected number of junction reads for an isoform is proportional to the product of its abundance ($\\theta$), the effective detectable junction length ($L$), the junction-specific detection efficiency ($\\alpha$), and the library size ($N$). For a given replicate $j$, the observed inclusion counts ($I_j$) and exclusion counts ($E_j$) can be modeled as:\n$$\nI_j \\approx k \\cdot \\theta_{I,j} \\cdot L_I \\cdot \\alpha_I \\cdot N_j\n$$\n$$\nE_j \\approx k \\cdot \\theta_{E,j} \\cdot L_E \\cdot \\alpha_E \\cdot N_j\n$$\nwhere $k$ is a technology-dependent proportionality constant and $j$ indexes the replicate. The library size $N_j$ is given in millions of mapped reads, so we can write $N_j = s_j \\times 10^6$ where $s_j$ is the value provided.\n\nTo estimate the abundance $\\theta$, we must correct the raw read counts for the biases introduced by length, efficiency, and library size. A \"corrected count\" for a replicate $j$, which is proportional to the true isoform abundance, can be defined by rearranging the model equations:\n$$\nI'_j = \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot N_j} \\propto \\theta_{I,j}\n$$\n$$\nE'_j = \\frac{E_j}{L_E \\cdot \\alpha_E \\cdot N_j} \\propto \\theta_{E,j}\n$$\nThe problem specifies that the condition-level inclusion fraction, $\\Psi_C$, for a condition $C$ (Normal or Tumor) is estimated by pooling these corrected counts across all replicates $j$ belonging to that condition. The pooled corrected counts are:\n$$\nI'_{C, \\text{pooled}} = \\sum_{j \\in C} I'_j = \\sum_{j \\in C} \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot N_j}\n$$\n$$\nE'_{C, \\text{pooled}} = \\sum_{j \\in C} E'_j = \\sum_{j \\in C} \\frac{E_j}{L_E \\cdot \\alpha_E \\cdot N_j}\n$$\nThe estimator for $\\Psi_C$ is then the ratio of the pooled corrected inclusion count to the sum of both pooled corrected counts:\n$$\n\\Psi_C = \\frac{I'_{C, \\text{pooled}}}{I'_{C, \\text{pooled}} + E'_{C, \\text{pooled}}} = \\frac{\\sum_{j \\in C} \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot N_j}}{\\sum_{j \\in C} \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot N_j} + \\sum_{j \\in C} \\frac{E_j}{L_E \\cdot \\alpha_E \\cdot N_j}}\n$$\nWe can substitute $N_j = s_j \\times 10^6$. The factor of $10^6$ is common to all terms in the numerator and denominator and thus cancels out. We can therefore use the given library size values $s_j$ directly in the formula:\n$$\n\\Psi_C = \\frac{\\sum_{j \\in C} \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot s_j}}{\\sum_{j \\in C} \\frac{I_j}{L_I \\cdot \\alpha_I \\cdot s_j} + \\sum_{j \\in C} \\frac{E_j}{L_E \\cdot \\alpha_E \\cdot s_j}}\n$$\nThis expression can be simplified by factoring out the constant terms $L_I \\alpha_I$ and $L_E \\alpha_E$:\n$$\n\\Psi_C = \\frac{\\frac{1}{L_I \\alpha_I} \\sum_{j \\in C} \\frac{I_j}{s_j}}{\\frac{1}{L_I \\alpha_I} \\sum_{j \\in C} \\frac{I_j}{s_j} + \\frac{1}{L_E \\alpha_E} \\sum_{j \\in C} \\frac{E_j}{s_j}}\n$$\nFirst, we calculate the normalization factors from the given parameters: $L_{I} = 140$, $L_{E} = 160$, $\\alpha_{I} = 0.90$, $\\alpha_{E} = 0.95$.\n$$\nw_I = L_I \\alpha_I = 140 \\times 0.90 = 126\n$$\n$$\nw_E = L_E \\alpha_E = 160 \\times 0.95 = 152\n$$\nNext, we compute the sums of the library-size-normalized counts for each condition. For the Normal (N) condition, with replicates $\\mathrm{N}_1$ and $\\mathrm{N}_2$:\n$$\n\\sum_{j \\in N} \\frac{I_j}{s_j} = \\frac{I_{\\mathrm{N}_{1}}}{s_{\\mathrm{N}_{1}}} + \\frac{I_{\\mathrm{N}_{2}}}{s_{\\mathrm{N}_{2}}} = \\frac{480}{40} + \\frac{720}{60} = 12 + 12 = 24\n$$\n$$\n\\sum_{j \\in N} \\frac{E_j}{s_j} = \\frac{E_{\\mathrm{N}_{1}}}{s_{\\mathrm{N}_{1}}} + \\frac{E_{\\mathrm{N}_{2}}}{s_{\\mathrm{N}_{2}}} = \\frac{1520}{40} + \\frac{2100}{60} = 38 + 35 = 73\n$$\nNow we calculate $\\Psi_N$:\n$$\n\\Psi_N = \\frac{\\frac{1}{126} \\times 24}{\\frac{1}{126} \\times 24 + \\frac{1}{152} \\times 73} = \\frac{24/126}{24/126 + 73/152} = \\frac{4/21}{4/21 + 73/152} = \\frac{608}{2141}\n$$\nNext, for the Tumor (T) condition, with replicates $\\mathrm{T}_1$ and $\\mathrm{T}_2$:\n$$\n\\sum_{j \\in T} \\frac{I_j}{s_j} = \\frac{I_{\\mathrm{T}_{1}}}{s_{\\mathrm{T}_{1}}} + \\frac{I_{\\mathrm{T}_{2}}}{s_{\\mathrm{T}_{2}}} = \\frac{2200}{50} + \\frac{2600}{55} = 44 + \\frac{520}{11} = \\frac{484+520}{11} = \\frac{1004}{11}\n$$\n$$\n\\sum_{j \\in T} \\frac{E_j}{s_j} = \\frac{E_{\\mathrm{T}_{1}}}{s_{\\mathrm{T}_{1}}} + \\frac{E_{\\mathrm{T}_{2}}}{s_{\\mathrm{T}_{2}}} = \\frac{800}{50} + \\frac{900}{55} = 16 + \\frac{180}{11} = \\frac{176+180}{11} = \\frac{356}{11}\n$$\nNow we calculate $\\Psi_T$. The common factor of $1/11$ will cancel in the numerator and denominator sums.\n$$\n\\Psi_T = \\frac{\\frac{1}{126} \\times \\frac{1004}{11}}{\\frac{1}{126} \\times \\frac{1004}{11} + \\frac{1}{152} \\times \\frac{356}{11}} = \\frac{1004/126}{1004/126 + 356/152} = \\frac{502/63}{502/63 + 89/38} = \\frac{19076}{24683}\n$$\nFinally, we compute the change in the percent spliced-in, $\\Delta\\Psi = \\Psi_T - \\Psi_N$.\n$$\n\\Delta\\Psi = \\frac{19076}{24683} - \\frac{608}{2141}\n$$\nUsing a common denominator of $24683 \\times 2141 = 52844303$:\n$$\n\\Delta\\Psi = \\frac{19076 \\times 2141 - 608 \\times 24683}{52844303} = \\frac{40841716 - 15007264}{52844303} = \\frac{25834452}{52844303}\n$$\nConverting this fraction to a decimal:\n$$\n\\Delta\\Psi \\approx 0.4888806\n$$\nRounding to four significant figures, we get $0.4889$.", "answer": "$$\n\\boxed{0.4889}\n$$", "id": "4378180"}, {"introduction": "A central challenge in genomic diagnostics is to predict the functional consequences of genetic variants identified in patients. This problem introduces a powerful computational approach used to assess how single nucleotide variants may disrupt splice site recognition. You will work with the Maximum Entropy Scan (MaxEntScan) model to calculate the change in a splice donor site score caused by a variant, translating a change in DNA sequence into a quantitative prediction of splicing disruption and linking it mechanistically to U1 snRNP binding [@problem_id:4378203].", "problem": "A clinical genomics laboratory uses Maximum Entropy Scan (MaxEntScan) to prioritize variants that perturb the $5^{\\prime}$ splice donor site in the context of precision medicine. The Maximum Entropy Scan (MaxEntScan) framework models the donor site as a constrained categorical distribution over a $9$-mer window spanning positions $-3$ to $+6$ relative to the exon-intron junction, while the genomic background is modeled as an unconstrained categorical distribution. Let the log-odds score be measured in bits, defined as the base-$2$ logarithm of the odds that the observed features arise from the splice-donor distribution rather than from the genomic background distribution. The maximum entropy principle states that the model distribution is the one of highest entropy subject to the observed feature constraints; in this setting, the score decomposes over the features used by the model.\n\nConsider an expressed gene with a reference $9$-mer donor window $\\text{A G G | G T A C G T}$, where the vertical bar denotes the exon-intron boundary, and a single-nucleotide variant changes the nucleotide at position $+5$ from $\\text{G}$ to $\\text{A}$. For this site, assume the model uses the following three features, each defined as a categorical variable and scored by its probability under the splice-donor class versus the genomic background class:\n\n- Feature $f_{1}$: the single nucleotide at position $+5$.\n- Feature $f_{2}$: the dinucleotide at positions $+4,+5$.\n- Feature $f_{3}$: the trinucleotide at positions $+3,+4,+5$.\n\nAll other features of the site remain unchanged and, by construction, their contributions cancel when taking the difference in scores between the variant and reference sequences. The laboratory has estimated the following class-conditional probabilities for the affected features:\n\n- For $f_{1}$ (position $+5$): reference $\\text{G}$ has splice-donor probability $P_{s}(f_{1}=\\text{G})=0.35$ and background probability $P_{b}(f_{1}=\\text{G})=0.15$; variant $\\text{A}$ has splice-donor probability $P_{s}(f_{1}=\\text{A})=0.08$ and background probability $P_{b}(f_{1}=\\text{A})=0.12$.\n- For $f_{2}$ (positions $+4,+5$): reference $\\text{C G}$ has splice-donor probability $P_{s}(f_{2}=\\text{CG})=0.20$ and background probability $P_{b}(f_{2}=\\text{CG})=0.05$; variant $\\text{C A}$ has splice-donor probability $P_{s}(f_{2}=\\text{CA})=0.09$ and background probability $P_{b}(f_{2}=\\text{CA})=0.06$.\n- For $f_{3}$ (positions $+3,+4,+5$): reference $\\text{A C G}$ has splice-donor probability $P_{s}(f_{3}=\\text{ACG})=0.12$ and background probability $P_{b}(f_{3}=\\text{ACG})=0.02$; variant $\\text{A C A}$ has splice-donor probability $P_{s}(f_{3}=\\text{ACA})=0.05$ and background probability $P_{b}(f_{3}=\\text{ACA})=0.03$.\n\nStarting from the definition of a log-odds score constructed under the maximum entropy principle, derive and compute the change in Maximum Entropy Scan score, $\\Delta S$, in bits, defined as the variant score minus the reference score. Round your final numerical answer to four significant figures and express it in bits. Briefly interpret the expected effect of this change on donor site strength in terms of recognition by U1 small nuclear RNA (U1 snRNA) and potential consequences for alternative splicing in a precision diagnostics context.", "solution": "The problem requires the calculation of the change in the Maximum Entropy Scan (MaxEntScan) score for a single-nucleotide variant at a $5^{\\prime}$ splice donor site, followed by an interpretation of the result.\n\nFirst, we establish the theoretical framework as defined in the problem. The log-odds score, $S$, is measured in bits and is defined as the base-$2$ logarithm of the odds ratio of the probabilities of observing a set of features under the splice-donor model ($P_s$) versus the genomic background model ($P_b$). For a given sequence represented by its features $f = \\{f_1, f_2, \\dots, f_n\\}$, the score is:\n$$S = \\log_2\\left(\\frac{P_s(f)}{P_b(f)}\\right)$$\nThe problem states that under the maximum entropy principle, the score decomposes over the features used by the model. This is an important simplification, implying that the total score is the sum of the scores for individual features.\n$$S = \\sum_i S(f_i) = \\sum_i \\log_2\\left(\\frac{P_s(f_i)}{P_b(f_i)}\\right)$$\nThe reference sequence has a $9$-mer donor window $\\text{A G G | G T A C G T}$. The variant changes the nucleotide at position $+5$ from $\\text{G}$ to $\\text{A}$. We are asked to compute the change in score, $\\Delta S$, which is the variant score, $S_{\\text{var}}$, minus the reference score, $S_{\\text{ref}}$.\n$$\\Delta S = S_{\\text{var}} - S_{\\text{ref}}$$\nThe problem specifies that only three features, $f_1, f_2, f_3$, are affected by this variant, and the contributions from all other features cancel out in the calculation of $\\Delta S$.\n- Feature $f_1$: nucleotide at position $+5$. For the reference sequence, this is $\\text{G}$; for the variant, it is $\\text{A}$.\n- Feature $f_2$: dinucleotide at positions $+4,+5$. For the reference, this is $\\text{CG}$; for the variant, it is $\\text{CA}$.\n- Feature $f_3$: trinucleotide at positions $+3,+4,+5$. For the reference, this is $\\text{ACG}$; for the variant, it is $\\text{ACA}$.\n\nThe change in score $\\Delta S$ is the sum of the changes in scores for each of these three features:\n$$\\Delta S = \\Delta S_1 + \\Delta S_2 + \\Delta S_3$$\nwhere $\\Delta S_i = S_{\\text{var}}(f_i) - S_{\\text{ref}}(f_i)$.\n\nLet's derive the expression for $\\Delta S$.\nFor feature $f_1$:\n$S_{\\text{ref}}(f_1) = \\log_2\\left(\\frac{P_s(f_1=\\text{G})}{P_b(f_1=\\text{G})}\\right)$\n$S_{\\text{var}}(f_1) = \\log_2\\left(\\frac{P_s(f_1=\\text{A})}{P_b(f_1=\\text{A})}\\right)$\n$\\Delta S_1 = S_{\\text{var}}(f_1) - S_{\\text{ref}}(f_1) = \\log_2\\left(\\frac{P_s(f_1=\\text{A})}{P_b(f_1=\\text{A})}\\right) - \\log_2\\left(\\frac{P_s(f_1=\\text{G})}{P_b(f_1=\\text{G})}\\right)$\n\nFor feature $f_2$:\n$S_{\\text{ref}}(f_2) = \\log_2\\left(\\frac{P_s(f_2=\\text{CG})}{P_b(f_2=\\text{CG})}\\right)$\n$S_{\\text{var}}(f_2) = \\log_2\\left(\\frac{P_s(f_2=\\text{CA})}{P_b(f_2=\\text{CA})}\\right)$\n$\\Delta S_2 = S_{\\text{var}}(f_2) - S_{\\text{ref}}(f_2) = \\log_2\\left(\\frac{P_s(f_2=\\text{CA})}{P_b(f_2=\\text{CA})}\\right) - \\log_2\\left(\\frac{P_s(f_2=\\text{CG})}{P_b(f_2=\\text{CG})}\\right)$\n\nFor feature $f_3$:\n$S_{\\text{ref}}(f_3) = \\log_2\\left(\\frac{P_s(f_3=\\text{ACG})}{P_b(f_3=\\text{ACG})}\\right)$\n$S_{\\text{var}}(f_3) = \\log_2\\left(\\frac{P_s(f_3=\\text{ACA})}{P_b(f_3=\\text{ACA})}\\right)$\n$\\Delta S_3 = S_{\\text{var}}(f_3) - S_{\\text{ref}}(f_3) = \\log_2\\left(\\frac{P_s(f_3=\\text{ACA})}{P_b(f_3=\\text{ACA})}\\right) - \\log_2\\left(\\frac{P_s(f_3=\\text{ACG})}{P_b(f_3=\\text{ACG})}\\right)$\n\nThe total change in score is the sum:\n$\\Delta S = (S_{\\text{var}}(f_1) - S_{\\text{ref}}(f_1)) + (S_{\\text{var}}(f_2) - S_{\\text{ref}}(f_2)) + (S_{\\text{var}}(f_3) - S_{\\text{ref}}(f_3))$\nUsing the logarithm property $\\log x + \\log y = \\log(xy)$, we can combine the terms:\n$\\Delta S = \\log_2\\left(\\frac{P_s(f_1=\\text{A})}{P_b(f_1=\\text{A})}\\right) + \\log_2\\left(\\frac{P_s(f_2=\\text{CA})}{P_b(f_2=\\text{CA})}\\right) + \\log_2\\left(\\frac{P_s(f_3=\\text{ACA})}{P_b(f_3=\\text{ACA})}\\right) - \\left[ \\log_2\\left(\\frac{P_s(f_1=\\text{G})}{P_b(f_1=\\text{G})}\\right) + \\log_2\\left(\\frac{P_s(f_2=\\text{CG})}{P_b(f_2=\\text{CG})}\\right) + \\log_2\\left(\\frac{P_s(f_3=\\text{ACG})}{P_b(f_3=\\text{ACG})}\\right) \\right]$\n\nNow, we substitute the given probability values into these expressions to compute the numerical value of $\\Delta S$.\nThe given probabilities are:\n- $P_s(f_1=\\text{G})=0.35$, $P_b(f_1=\\text{G})=0.15$\n- $P_s(f_1=\\text{A})=0.08$, $P_b(f_1=\\text{A})=0.12$\n- $P_s(f_2=\\text{CG})=0.20$, $P_b(f_2=\\text{CG})=0.05$\n- $P_s(f_2=\\text{CA})=0.09$, $P_b(f_2=\\text{CA})=0.06$\n- $P_s(f_3=\\text{ACG})=0.12$, $P_b(f_3=\\text{ACG})=0.02$\n- $P_s(f_3=\\text{ACA})=0.05$, $P_b(f_3=\\text{ACA})=0.03$\n\nCalculating the change for each feature:\n$\\Delta S_1 = \\log_2\\left(\\frac{0.08}{0.12}\\right) - \\log_2\\left(\\frac{0.35}{0.15}\\right) = \\log_2\\left(\\frac{2}{3}\\right) - \\log_2\\left(\\frac{7}{3}\\right) = \\log_2\\left(\\frac{2/3}{7/3}\\right) = \\log_2\\left(\\frac{2}{7}\\right)$\n$\\Delta S_2 = \\log_2\\left(\\frac{0.09}{0.06}\\right) - \\log_2\\left(\\frac{0.20}{0.05}\\right) = \\log_2\\left(\\frac{3}{2}\\right) - \\log_2(4) = \\log_2\\left(\\frac{3/2}{4}\\right) = \\log_2\\left(\\frac{3}{8}\\right)$\n$\\Delta S_3 = \\log_2\\left(\\frac{0.05}{0.03}\\right) - \\log_2\\left(\\frac{0.12}{0.02}\\right) = \\log_2\\left(\\frac{5}{3}\\right) - \\log_2(6) = \\log_2\\left(\\frac{5/3}{6}\\right) = \\log_2\\left(\\frac{5}{18}\\right)$\n\nThe total change in score is the sum of these individual changes:\n$\\Delta S = \\Delta S_1 + \\Delta S_2 + \\Delta S_3 = \\log_2\\left(\\frac{2}{7}\\right) + \\log_2\\left(\\frac{3}{8}\\right) + \\log_2\\left(\\frac{5}{18}\\right)$\nUsing the logarithm property again:\n$\\Delta S = \\log_2\\left(\\frac{2}{7} \\times \\frac{3}{8} \\times \\frac{5}{18}\\right) = \\log_2\\left(\\frac{30}{1008}\\right)$\nSimplifying the fraction:\n$\\frac{30}{1008} = \\frac{15}{504} = \\frac{5}{168}$\nSo, the exact change in score is:\n$\\Delta S = \\log_2\\left(\\frac{5}{168}\\right)$\nTo find the numerical value, we can use the change of base formula, $\\log_2(x) = \\frac{\\ln(x)}{\\ln(2)}$:\n$\\Delta S = \\frac{\\ln(5/168)}{\\ln(2)} \\approx \\frac{\\ln(0.0297619)}{\\ln(2)} \\approx \\frac{-3.514553}{0.693147} \\approx -5.070481$\nRounding the result to four significant figures, we get $-5.070$.\n\nThe change in score is $\\Delta S \\approx -5.070$ bits.\n\nBrief interpretation of the result:\nThe computed change in the MaxEntScan score, $\\Delta S \\approx -5.070$ bits, is a large negative value. This indicates a substantial reduction in the predicted strength of the $5^{\\prime}$ splice donor site due to the variant.\nIn the context of pre-mRNA splicing, the $5^{\\prime}$ splice site sequence is recognized and bound by the U1 small nuclear RNA (snRNA), a component of the U1 snRNP. The MaxEntScan score is a proxy for the information content of the site and is correlated with U1 binding affinity. A large decrease in the score strongly suggests that the variant significantly weakens the binding of the U1 snRNP to the donor site.\nThis impaired recognition by the splicing machinery can lead to several alternative splicing outcomes, such as:\n1. Exon skipping, where the exon upstream of the weakened site is excluded from the final mRNA.\n2. Use of a nearby cryptic splice site, leading to an altered mRNA sequence.\n3. Intron retention, where the intron is not removed.\nAny of these outcomes can result in a frameshift or the introduction of a premature termination codon, leading to the production of a truncated or non-functional protein, or degradation of the transcript via nonsense-mediated decay (NMD).\nIn a precision diagnostics context, a variant causing such a dramatic drop in a splice site score is considered strong evidence of pathogenicity. It provides a clear, quantitative mechanistic hypothesis for how the genetic change leads to disease, justifying its prioritization for functional studies and its potential use in clinical decision-making.", "answer": "$$\n\\boxed{-5.070}\n$$", "id": "4378203"}]}